GLP-1 Pipeline, Coverage & Long-Term Outcomes

Oral orforglipron was approved in April 2026, Medicare coverage began July 1 at $50 per month, and retatrutide is expected to file in Q1 2027. Investigational CagriSema has reported promising company topline results, while durability, body composition, affordability, response variation, nutrition needs, and long-term outcomes remain unsettled.